The estimated Net Worth of Robert A. Michael is at least $48.1 Million dollars as of 28 February 2024. Mr. Michael owns over 68,879 units of Abbvie Inc stock worth over $19,195,331 and over the last 8 years he sold ABBV stock worth over $20,100,776. In addition, he makes $8,772,850 as Chief Financial Officer and Senior Vice President at Abbvie Inc.
Robert has made over 6 trades of the Abbvie Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 68,879 units of ABBV stock worth $12,153,700 on 28 February 2024.
The largest trade he's ever made was selling 68,879 units of Abbvie Inc stock on 28 February 2024 worth over $12,153,700. On average, Robert trades about 7,594 units every 150 days since 2017. As of 28 February 2024 he still owns at least 98,645 units of Abbvie Inc stock.
You can see the complete history of Mr. Michael stock trades at the bottom of the page.
Robert A. Michael serves as Chief Financial Officer, Senior Vice President of the Company. Mr. Michael has been AbbVie’s Vice President, Controller, since March 1, 2017 and served as AbbVie’s Vice President, Treasurer from 2015 to 2016, and as Vice President, Controller, Commercial Operations from 2013 to 2015. He joined Abbott Laboratories in 1993 and held numerous positions in the finance organization.
As the Chief Financial Officer and Senior Vice President of Abbvie Inc, the total compensation of Robert Michael at Abbvie Inc is $8,772,850. There are 4 executives at Abbvie Inc getting paid more, with Richard Gonzalez having the highest compensation of $21,610,600.
Robert Michael is 49, he's been the Chief Financial Officer and Senior Vice President of Abbvie Inc since 2018. There are 29 older and 3 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.
Robert's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60044, United States.
Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell, and Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Abbvie Inc executives and other stock owners filed with the SEC include: